

Francisco M Marty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4171487/publications.pdf>

Version: 2024-02-01

267
papers

15,604
citations

22099

59
h-index

19690

117
g-index

276
all docs

276
docs citations

276
times ranked

17163
citing authors

#	ARTICLE	IF	CITATIONS
1	Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1827-1837.	13.9	1,152
2	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1048.	3.8	1,032
3	Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. <i>New England Journal of Medicine</i> , 2022, 386, 305-315.	13.9	813
4	Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 2433-2444.	13.9	796
5	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	4.6	528
6	Transmission of Lymphocytic Choriomeningitis Virus by Organ Transplantation. <i>New England Journal of Medicine</i> , 2006, 354, 2235-2249.	13.9	491
7	Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell Transplants. <i>New England Journal of Medicine</i> , 2004, 350, 950-952.	13.9	412
8	Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation. <i>Annals of Internal Medicine</i> , 2014, 161, 319.	2.0	370
9	CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2013, 369, 1227-1236.	13.9	336
10	Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 284-292.	4.6	315
11	Persistent and Relapsing Babesiosis in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2008, 46, 370-376.	2.9	299
12	Post-transplant acute limbic encephalitis. <i>Neurology</i> , 2007, 69, 156-165.	1.5	268
13	Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders. <i>Clinical Infectious Diseases</i> , 2006, 43, 16-24.	2.9	255
14	Three Patients with Full Facial Transplantation. <i>New England Journal of Medicine</i> , 2012, 366, 715-722.	13.9	230
15	Diagnostic Performance of the (1â†’3)â€²â€²Glucan Assay for Invasive Fungal Disease. <i>Clinical Infectious Diseases</i> , 2009, 49, 1650-1659.	2.9	204
16	How to Obtain a Nasopharyngeal Swab Specimen. <i>New England Journal of Medicine</i> , 2020, 382, e76.	13.9	199
17	Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. <i>Blood</i> , 2003, 102, 2768-2776.	0.6	196
18	Emergence of a Clinical Daptomycin-Resistant <i>Staphylococcus aureus</i> Isolate during Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia and Osteomyelitis. <i>Journal of Clinical Microbiology</i> , 2006, 44, 595-597.	1.8	178

#	ARTICLE	IF	CITATIONS
19	Serious Infections Among Adult Medicaid Beneficiaries With Systemic Lupus Erythematosus and Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1577-1585.	2.9	177
20	Molecular Methods To Improve Diagnosis and Identification of Mucormycosis. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2151-2153.	1.8	162
21	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 369-381.	2.0	151
22	Sequence-Based Discovery of <i>Bradyrhizobium enterica</i> in Cord Colitis Syndrome. <i>New England Journal of Medicine</i> , 2013, 369, 517-528.	13.9	148
23	A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. <i>Blood</i> , 2014, 124, 2921-2929.	0.6	145
24	Cord-Blood Hematopoietic Stem Cell Transplant Confers an Increased Risk for Human Herpesvirus-6-Associated Acute Limbic Encephalitis: A Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1638-1648.	2.0	141
25	Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1049-1059.	2.0	138
26	Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1255-1264.	2.9	137
27	Reactivity of (1 α) ³ - β -D-Glucan Assay with Commonly Used Intravenous Antimicrobials. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3450-3453.	1.4	136
28	Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. <i>Blood</i> , 2007, 110, 490-500.	0.6	136
29	A Breath Fungal Secondary Metabolite Signature to Diagnose Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1733-1740.	2.9	129
30	Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 359-370.	2.0	127
31	Role of (1 α) ³ - β -D-glucan in the diagnosis of invasive aspergillosis. <i>Medical Mycology</i> , 2009, 47, S233-S240.	0.3	123
32	Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. <i>Transplant Infectious Disease</i> , 2010, 12, 489-496.	0.7	116
33	Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. <i>Transplant Infectious Disease</i> , 2012, 14, 452-460.	0.7	112
34	Cord Colitis Syndrome in Cord-Blood Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2011, 365, 815-824.	13.9	103
35	Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 552-559.	2.0	102
36	A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 70, 1525-1533.	2.9	100

#	ARTICLE	IF	CITATIONS
37	The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allograft. <i>American Journal of Transplantation</i> , 2014, 14, 1446-1452.	2.6	97
38	Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 690-701.	2.9	97
39	Treatment of Human Disseminated Strongyloidiasis with a Parenteral Veterinary Formulation of Ivermectin. <i>Clinical Infectious Diseases</i> , 2005, 41, e5-e8.	2.9	96
40	Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 2159-2175.	2.5	89
41	How to Obtain a Nasopharyngeal Swab Specimen. <i>New England Journal of Medicine</i> , 2020, 383, e14.	13.9	86
42	Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 135-146.	5.2	85
43	Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1460-1465.	1.3	84
44	(1 α ,25)-D-Glucan Assay Positivity in Patients with Pneumocystis (carinii) jirovecii Pneumonia. <i>Annals of Internal Medicine</i> , 2007, 147, 70.	2.0	83
45	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1037-1042.	0.5	83
46	Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1255-1260.	1.8	82
47	Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. <i>Transplant Infectious Disease</i> , 2007, 9, 121-125.	0.7	81
48	Maribavir and human cytomegalovirus—what happened in the clinical trials and why might the drug have failed?. <i>Current Opinion in Virology</i> , 2011, 1, 555-562.	2.6	81
49	A CRISPR-based assay for the detection of opportunistic infections post-transplantation and for the monitoring of transplant rejection. <i>Nature Biomedical Engineering</i> , 2020, 4, 601-609.	11.6	80
50	Infectious Complications Associated with Immunomodulating Biologic Agents. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 285-306.	1.9	78
51	Disseminated dermatophytosis in a patient with hereditary hemochromatosis and hepatic cirrhosis: case report and review of the literature. <i>Medical Mycology</i> , 2010, 48, 518-527.	0.3	75
52	Cefepime vs Other Antibacterial Agents for the Treatment of Enterobacter Species Bacteremia. <i>Clinical Infectious Diseases</i> , 2014, 58, 1554-1563.	2.9	75
53	Respiratory Virus Detection in Immunocompromised Patients with FilmArray Respiratory Panel Compared to Conventional Methods. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3216-3221.	1.8	68
54	Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 434-438.	2.0	66

#	ARTICLE	IF	CITATIONS
55	Vascularized composite tissue allotransplantation â€“ state of the art. <i>Clinical Transplantation</i> , 2013, 27, 330-337.	0.8	66
56	Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. <i>Arthritis and Rheumatology</i> , 2017, 69, 387-397.	2.9	65
57	BK Virus Disease after Allogeneic Stem Cell Transplantation: A Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 564-570.	2.0	61
58	Invasive fungal disease in patients treated for newly diagnosed acute leukemia. <i>American Journal of Hematology</i> , 2010, 85, 695-699.	2.0	60
59	Xenotropic Murine Leukemia Virusâ€“Related Virus Prevalence in Patients with Chronic Fatigue Syndrome or Chronic Immunomodulatory Conditions. <i>Journal of Infectious Diseases</i> , 2010, 202, 1478-1481.	1.9	60
60	Isavuconazole Treatment of a Patient with Disseminated Mucormycosis. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1016-1019.	1.8	60
61	New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	59
62	Clinical potential of <sc>DAS</sc>181 for treatment of parainfluenzaâ€“3 infections in transplant recipients. <i>Transplant Infectious Disease</i> , 2012, 14, 427-433.	0.7	58
63	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Womenâ€™s Cancer Center Multidisciplinary Guideline. <i>Oncologist</i> , 2017, 22, 343-350.	1.9	57
64	Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: A retrospective, observational, sequential cohort analysis. <i>Clinical Therapeutics</i> , 2010, 32, 637-648.	1.1	56
65	Treatment of Parainfluenza 3 Infection With DAS181 in a Patient After Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2011, 53, e77-e80.	2.9	56
66	Torsades de pointes associated with voriconazole use. <i>Transplant Infectious Disease</i> , 2007, 9, 33-36.	0.7	55
67	The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. <i>Transplant International</i> , 2006, 19, 2-11.	0.8	54
68	Recovery of <i>Herbaspirillum</i> Species from Persons with Cystic Fibrosis. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2774-2777.	1.8	53
69	Post-diagnostic kinetics of the (1 â†’ 3)-Î²-d-glucan assay in invasive aspergillosis, invasive candidiasis and <i>Pneumocystis jirovecii</i> pneumonia. <i>Clinical Microbiology and Infection</i> , 2012, 18, E122-E127.	2.8	53
70	Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv099.	0.4	53
71	A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2777-2786.	2.9	53
72	Disseminated Trichosporonosis Caused by <i>Trichosporon loubieri</i> . <i>Journal of Clinical Microbiology</i> , 2003, 41, 5317-5320.	1.8	52

#	ARTICLE	IF	CITATIONS
73	Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	52
74	Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study. <i>Journal of Infectious Diseases</i> , 2014, 209, 542-550.	1.9	51
75	Live Attenuated Varicella-Zoster Vaccine in Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 285-287.	2.0	51
76	Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. <i>Medical Mycology</i> , 2020, 58, 417-424.	0.3	48
77	Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. <i>Annals of Oncology</i> , 2018, 29, 2141-2142.	0.6	47
78	Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia. <i>PLoS ONE</i> , 2015, 10, e0140930.	1.1	46
79	Five-Year Follow-up after Face Transplantation. <i>New England Journal of Medicine</i> , 2019, 380, 2579-2581.	13.9	46
80	Incidence and risk factors for herpes zoster following heart transplantation. <i>Transplant Infectious Disease</i> , 2014, 16, 17-25.	0.7	45
81	Initial Experience of Dual Maintenance Immunosuppression With Steroid Withdrawal in Vascular Composite Tissue Allograft Transplantation. <i>American Journal of Transplantation</i> , 2015, 15, 1421-1431.	2.6	45
82	American Society for Transplantation and Cellular Therapy Series: "Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 707-719.	0.6	45
83	Disseminated <i>Geotrichum candidum</i> infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature. <i>Transplant Infectious Disease</i> , 2009, 11, 458-462.	0.7	44
84	A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. <i>Clinical Infectious Diseases</i> , 2020, 71, 2787-2795.	2.9	44
85	<i>Gordonia bronchialis</i> Bacteremia and Pleural Infection: Case Report and Review of the Literature. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1662-1666.	1.8	42
86	Infections Following Facial Composite Tissue Allograft Transplantation-Single Center Experience and Review of the Literature. <i>American Journal of Transplantation</i> , 2013, 13, 770-779.	2.6	42
87	Risk of hepatitis B virus reactivation in patients treated with ibrutinib. <i>Blood</i> , 2018, 131, 1987-1989.	0.6	42
88	Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 1703-1711.	2.6	42
89	DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. <i>Transplant Infectious Disease</i> , 2014, 16, 141-144.	0.7	41
90	Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. <i>Journal of Infectious Diseases</i> , 2017, 216, 254-262.	1.9	41

#	ARTICLE	IF	CITATIONS
91	Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. <i>Med</i> , 2021, 2, 411-422.e5.	2.2	41
92	Post-Babesiosis Warm Autoimmune Hemolytic Anemia. <i>New England Journal of Medicine</i> , 2017, 376, 939-946.	13.9	40
93	<i>Cryptosporidium parvum</i> cerebral phaeohyphomycosis: case report of successful surgical excision and voriconazole treatment and review. <i>Medical Mycology</i> , 2010, 48, 769-774.	0.3	39
94	Mortality in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients with Mucormycosis, 2001 to 2009. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5018-5021.	1.4	39
95	Utility of Sentinel Flaps in Assessing Facial Allograft Rejection. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 250-258.	0.7	39
96	Human herpesvirus 6 encephalitis. <i>Current Infectious Disease Reports</i> , 2008, 10, 292-9.	1.3	38
97	Antifungal use in HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 91-102.	0.9	37
98	A Targeted Peritransplant Antifungal Strategy for the Prevention of Invasive Fungal Disease After Lung Transplantation. <i>Transplantation</i> , 2012, 94, 281-286.	0.5	36
99	Ask, Don't Tell – Mobile Phones to Improve HIV Care. <i>New England Journal of Medicine</i> , 2013, 369, 1867-1868.	13.9	36
100	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. <i>Lung Cancer</i> , 2020, 145, 181-185.	0.9	36
101	Infectious Complications Associated with Immunomodulating Biologic Agents. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 117-138.	0.9	34
102	<i>Pneumocystis jirovecii</i> pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 359-367.	1.1	34
103	Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S23.	2.0	34
104	Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid. <i>Arthritis Care and Research</i> , 2017, 69, 1620-1626.	1.5	34
105	Postoperative Antibacterial Prophylaxis for the Prevention of Infectious Complications Associated With Tube Thoracostomy in Patients Undergoing Elective General Thoracic Surgery. <i>JAMA Surgery</i> , 2013, 148, 440.	2.2	33
106	Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa415.	0.4	33
107	Isavuconazole for treatment of rare invasive fungal diseases. <i>Mycoses</i> , 2018, 61, 518-533.	1.8	32
108	Neurosyphilis Presenting as Herpes Simplex Encephalitis. <i>Clinical Infectious Diseases</i> , 2001, 32, 1108-1109.	2.9	31

#	ARTICLE	IF	CITATIONS
109	Management of Oral Infections in Cancer Patients. <i>Dental Clinics of North America</i> , 2008, 52, 129-153.	0.8	31
110	Risk factors for invasive fungal disease in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 227-232.	0.3	30
111	Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. <i>Transplant Infectious Disease</i> , 2013, 15, 163-170.	0.7	28
112	Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 942-945.	1.3	27
113	Cerebral phaeohyphomycosis caused by <i>Bipolaris spicifera</i> after heart transplantation. <i>Transplant Infectious Disease</i> , 2011, 13, 419-423.	0.7	25
114	Safety of Posaconazole and Sirolimus Coadministration in Allogeneic Hematopoietic Stem Cell Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1462-1465.	2.0	25
115	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. <i>Mycoses</i> , 2018, 61, 420-429.	1.8	25
116	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. <i>Mycoses</i> , 2018, 61, 485-497.	1.8	24
117	Accelerated chronic skin changes without allograft vasculopathy: A 10-year outcome report after face transplantation. <i>Surgery</i> , 2020, 167, 991-998.	1.0	23
118	Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2017, 65, 510-513.	2.9	22
119	Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation. <i>Clinical Infectious Diseases</i> , 2019, 69, 869-872.	2.9	22
120	Full facial retransplantation in a female patient—Technical, immunologic, and clinical considerations. <i>American Journal of Transplantation</i> , 2021, 21, 3472-3480.	2.6	21
121	POST-TRANSPLANT ACUTE LIMBIC ENCEPHALITIS: CLINICAL FEATURES AND RELATIONSHIP TO HHV6. <i>Neurology</i> , 2008, 70, 491-493.	1.5	20
122	Breath-Based Diagnosis of Invasive Mucormycosis (IM). <i>Open Forum Infectious Diseases</i> , 2017, 4, S53-S54.	0.4	20
123	Long-term Persistence of an Extensively Drug-Resistant Subclade of Globally Distributed <i>Pseudomonas aeruginosa</i> Clonal Complex 446 in an Academic Medical Center. <i>Clinical Infectious Diseases</i> , 2020, 71, 1524-1531.	2.9	20
124	Racial Disproportionality in Covid Clinical Trials. <i>New England Journal of Medicine</i> , 2020, 383, 2486-2490.	13.9	20
125	Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 4821-4830.	2.5	20
126	Cerebrospinal fluid <i>Coccidioides</i> antigen testing in the diagnosis and management of central nervous system coccidioidomycosis. <i>Mycoses</i> , 2015, 58, 598-602.	1.8	19

#	ARTICLE	IF	CITATIONS
127	<i>Strongyloides</i> hyperinfection syndrome and transplantation: a preventable, frequently fatal infection. <i>Transplant Infectious Disease</i> , 2009, 11, 97-99.	0.7	18
128	Infectious Granulomatous Dermatitis Associated With <i>Rothia mucilaginosa</i> Bacteremia: A Case Report. <i>American Journal of Dermatopathology</i> , 2010, 32, 175-179.	0.3	18
129	Efficacy and safety of micafungin for treatment of serious <i>Candida</i> infections in patients with or without malignant disease. <i>Mycoses</i> , 2011, 54, e838-e847.	1.8	18
130	Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?. <i>Mycoses</i> , 2019, 62, 413-417.	1.8	18
131	Diagnostic Efficacy and Safety of Computed Tomography-Guided Transthoracic Needle Biopsy in Patients with Hematologic Malignancies. <i>Academic Radiology</i> , 2009, 16, 1408-1415.	1.3	17
132	The polyomavirus puzzle: is host immune response beneficial in controlling BK virus after adult hematopoietic cell transplantation?. <i>Transplant Infectious Disease</i> , 2014, 16, 521-531.	0.7	17
133	DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e773-e781.	2.9	17
134	<i>Bradyrhizobium enterica</i> in Cord Colitis Syndrome. <i>New England Journal of Medicine</i> , 2013, 369, 1866-1867.	13.9	16
135	Fatal adenovirus encephalomyeloradiculitis in an umbilical cord stem cell transplant recipient. <i>Neurology</i> , 2013, 80, 1715-1717.	1.5	16
136	Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 253-260.	0.2	16
137	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 1881-1893.	2.5	16
138	Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	16
139	Treatment of Cavitory Pulmonary Zygomycosis With Surgical Resection and Posaconazole. <i>Annals of Thoracic Surgery</i> , 2006, 82, 338-340.	0.7	15
140	How Do We Manage Oral Infections in Allogeneic Stem Cell Transplantation and Other Severely Immunocompromised Patients?. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2011, 23, 579-599.	0.4	15
141	Long-Term Stability at 20°C of <i>Aspergillus Galactomannan</i> in Serum and Bronchoalveolar Lavage Specimens. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2108-2111.	1.8	15
142	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2938-2944.	1.3	15
143	Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT. <i>Blood</i> , 2020, 135, 1447-1451.	0.6	15
144	Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study. <i>Arthritis Care and Research</i> , 2021, 73, 146-157.	1.5	15

#	ARTICLE	IF	CITATIONS
145	When to change treatment of acute invasive aspergillosis: an expert viewpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 16-23.	1.3	15
146	Myiasis Due to <i>Dermatobia hominis</i> (Human Botfly). <i>New England Journal of Medicine</i> , 2005, 352, e21.	13.9	14
147	Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib. <i>Leukemia and Lymphoma</i> , 2019, 60, 527-530.	0.6	14
148	824An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis. <i>Open Forum Infectious Diseases</i> , 2014, 1, S235-S236.	0.4	13
149	Guillain-Barré syndrome associated with resistant cytomegalovirus infection after face transplantation. <i>Transplant Infectious Disease</i> , 2016, 18, 288-292.	0.7	13
150	Pathologies of oral and sinonasal mucosa following facial vascularized composite allotransplantation. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021, 74, 1562-1571.	0.5	13
151	Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. <i>Leukemia and Lymphoma</i> , 2022, 63, 1934-1941.	0.6	13
152	Resolution of diarrhea in an immunocompromised patient with chronic norovirus gastroenteritis correlates with constitution of specific antibody blockade titer. <i>Infection</i> , 2016, 44, 551-554.	2.3	12
153	Principles of antimicrobial therapy in the transplant patient. <i>Transplant Infectious Disease</i> , 2004, 6, 97-100.	0.7	11
154	Adjunctive management of central line-associated bloodstream infections with 70% ethanol-lock therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1665-1668.	1.3	11
155	Face Transplantation in a Highly Sensitized Recipient. <i>Military Medicine</i> , 2016, 181, 221-226.	0.4	11
156	Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. <i>Blood Advances</i> , 2021, 5, 54-60.	2.5	11
157	Lyme Meningoradiculitis and Myositis after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2005, 41, e112-e114.	2.9	10
158	Seasonal Variability Precipitating Hand Transplant Rejection?. <i>Transplantation</i> , 2017, 101, e313.	0.5	10
159	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. <i>Clinical Immunology</i> , 2019, 207, 18-23.	1.4	10
160	CMX001 for Prevention and Control of CMV Infection in CMV-Seropositive Allogeneic Stem-Cell Transplant Recipients: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial of Safety, Tolerability and Antiviral Activity. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S203-S204.	2.0	9
161	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1272-1276.	2.5	9
162	Invasive Fungal Carotiditis: A Rare Manifestation of Cranial Invasive Fungal Disease: Case Series and Systematic Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz392.	0.4	9

#	ARTICLE	IF	CITATIONS
163	Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis. <i>Mycoses</i> , 2020, 63, 58-64.	1.8	9
164	Invasive Fungal Disease after Remote Inoculation in Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2011, 52, e7-e10.	2.9	8
165	Cost analysis of dental services needed before hematopoietic cell transplantation. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 117, 59-66.	0.2	8
166	Cytomegalovirus events in high-risk allogeneic hematopoietic cell transplantation patients who received letermovir prophylaxis. <i>Transplant Infectious Disease</i> , 2021, 23, e13619.	0.7	8
167	BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation. <i>Transplant Immunology</i> , 2015, 32, 116-120.	0.6	7
168	Maribavir for Treatment of Cytomegalovirus (CMV) Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant (SCT) or Solid Organ Transplant (SOT) Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	7
169	Letermovir Prophylaxis for Cytomegalovirus. <i>New England Journal of Medicine</i> , 2018, 378, 963-965.	13.9	7
170	Invasive <i>Mycobacterium</i> fungal cellulitis and myositis. <i>Medical Mycology</i> , 2012, 50, 740-745.	0.3	6
171	Neutropenia Associated With Prolonged Daptomycin Use: Table 1.. <i>Clinical Infectious Diseases</i> , 2013, 56, 1353-1354.	2.9	6
172	Serologic Response to Hepatitis B Vaccination Among Lung Transplantation Candidates. <i>Transplantation</i> , 2014, 98, 676-679.	0.5	6
173	Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation. <i>PLoS ONE</i> , 2018, 13, e0197298.	1.1	6
174	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 221-228.	1.3	6
175	Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib. <i>Leukemia Research</i> , 2021, 108, 106610.	0.4	6
176	Pandemic H1N1 Influenza Infection in Adult Transplant Recipients. <i>Transplantation</i> , 2011, 91, e80-e81.	0.5	5
177	Elevated Serum Beta-d-Glucan Levels in Immunocompromised Children with Clinical Suspicion for <i>Pneumocystis jirovecii</i> Pneumonia. <i>Vaccine Journal</i> , 2011, 18, 1202-1203.	3.2	5
178	Serum Galactomannan and (1 \rightarrow 3)- β -Glucan Assays for Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1054-1056.	1.8	5
179	Clinical characteristics and outcomes of clostridial bacteraemia in cancer patients. <i>Clinical Microbiology and Infection</i> , 2014, 20, 752-757.	2.8	5
180	Green Herring Syndrome: Bacterial Infection in Patients With Mucormycosis Cavitory Lung Disease. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu014.	0.4	5

#	ARTICLE	IF	CITATIONS
181	The VITAL study: case control studies are hypothesis-generating â€“ Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 886-887.	4.6	5
182	Case 31-2019: A 45-Year-Old Woman with Headache and Somnolence. <i>New England Journal of Medicine</i> , 2019, 381, 1459-1470.	13.9	5
183	Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials. <i>Clinical Infectious Diseases</i> , 2021, 73, e1380-e1383.	2.9	5
184	1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI). <i>Open Forum Infectious Diseases</i> , 2020, 7, S642-S642.	0.4	5
185	Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allograft Transplantation: An International Multicenter Retrospective Cohort Study. <i>Transplantation</i> , 2022, 106, 2031-2043.	0.5	5
186	The persistent challenges of bacterial infections in the transplant recipient. <i>Transplant Infectious Disease</i> , 2006, 8, 125-127.	0.7	4
187	Opportunistic Infections (OIs) in Patients with Hematologic Malignancies (HM) Treated with Brutonâ€™s Tyrosine Kinase (BTK) and Phosphoinositide 3 Kinase (PI3K) Inhibitors: An 8-Year Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, S699-S699.	0.4	4
188	1715. A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Trial to Examine the Effects of DAS181 in Immunocompromised (IC) Patients With Parainfluenza Virus (PIV) Lower Respiratory Tract Infection (LRTI) on Supplemental Oxygen (SO). <i>Open Forum Infectious Diseases</i> , 2018, 5, S50-S51.	0.4	4
189	Osmotic Tubulopathy in a Patient With COVID-19 Treated With Remdesivir. <i>Kidney International Reports</i> , 2021, 6, 1987-1991.	0.4	4
190	Infection in the Hematopoietic Stem Cell Transplant Recipient. , 2008, , 421-448.		4
191	Reply to "Insufficient Demonstration of Long-Term Stability of Aspergillus Galactomannan". <i>Journal of Clinical Microbiology</i> , 2014, 52, 4119-4119.	1.8	3
192	Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2164-2165.	2.0	3
193	Reply to Singh. <i>Clinical Infectious Diseases</i> , 2020, 71, 471-472.	2.9	3
194	Fulminant <i>Acanthamoeba castellanii</i> Encephalitis in an Ibrutinib-Treated Patient. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa025.	0.4	3
195	Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab441.	0.4	3
196	Hepatitis B Virus Vaccination after Allogeneic Hematopoietic Cell Transplantation Prevents Post-Transplantation Hepatitis B Virus Reactivation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 402.e1-402.e5.	0.6	3
197	Posaconazole for Invasive Aspergillosis?. <i>Clinical Infectious Diseases</i> , 2007, 45, 664-664.	2.9	2
198	One-Year Safety and Immunogenicity of Two Formulations of an Adjuvanted Varicella-Zoster Virus (VZV) Subunit Candidate Vaccine in Adult Autologous Hematopoietic Cell Transplant (HCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S168-S169.	2.0	2

#	ARTICLE	IF	CITATIONS
199	Triple opportunistic pulmonary cavitary disease after cord blood transplantation. <i>Transplant Infectious Disease</i> , 2014, 16, 818-821.	0.7	2
200	Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S56-S57.	2.0	2
201	Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Open Forum Infectious Diseases</i> , 2017, 4, S311-S311.	0.4	2
202	90-Day Risk of Bloodstream Infections with Enteric Pathogens (BSI-EP) in Patients with Gastrointestinal Graft-Versus-Host Disease (GI-GVHD). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S375.	2.0	2
203	Eponychial lesions following bilateral upper extremity vascular composite allotransplantation: a case report. <i>Case Reports in Plastic Surgery & Hand Surgery</i> , 2018, 5, 14-17.	0.1	2
204	358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA). <i>Open Forum Infectious Diseases</i> , 2018, 5, S140-S141.	0.4	2
205	NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1412-1416.	2.5	2
206	Herpes Zoster Subunit Vaccination for Renal Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019, 70, 718-719.	2.9	2
207	Defibrotide formulations contain (1 α) ³ - β -D-glucan that could influence clinical diagnostic testing. <i>Bone Marrow Transplantation</i> , 2020, 55, 2045-2046.	1.3	2
208	Epidemiology and outcomes of invasive aspergillosis among pediatric immunocompromised patients: A 12-year single-center experience. <i>Medical Mycology</i> , 2022, 60, .	0.3	2
209	123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI). <i>Open Forum Infectious Diseases</i> , 2021, 8, S73-S74.	0.4	2
210	Transplant infectious disease as a subspecialty: does outlining how we train define who we are?. <i>Transplant Infectious Disease</i> , 2010, 12, 187-189.	0.7	1
211	Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1994-1994.	1.8	1
212	HIV-1 and 2009 H1N1 Influenza A in Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, e111-e113.	0.9	1
213	825A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole vs Voriconazole in Patients with Invasive Mold Disease (IMD): Outcomes in Patients with Pulmonary Infections. <i>Open Forum Infectious Diseases</i> , 2014, 1, S236-S236.	0.4	1
214	In Vitro Volatile Metabolite Signatures of Common Pathogenic Fusarium Species. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
215	Dasatinib Use May Be a Novel Risk Factor for Cytomegalovirus (CMV) Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
216	Introducing the Wiley Transplant Peer Review Network. <i>American Journal of Transplantation</i> , 2016, 16, 2505-2507.	2.6	1

#	ARTICLE	IF	CITATIONS
217	Use of Multimodality Imaging in Diagnosing Invasive Fungal Diseases of the Heart. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	1
218	1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S56-S57.	0.4	1
219	1564. Lower Rates of Epstein-Barr Virus (EBV) Viremia in Pediatric Solid Organ Transplant (SOT) Recipients Who Received Valganciclovir Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S487-S488.	0.4	1
220	Draft Genome Sequence of <i>Pseudomonas aeruginosa</i> Strain BWH047, a Sequence Type 235 Multidrug-Resistant Clinical Isolate Expressing High Levels of Colistin Resistance. <i>Microbiology Resource Announcements</i> , 2019, 8, .	0.3	1
221	Risk of HHV6-Associated Post-Transplant Acute Limbic Encephalitis (PALE) after Umbilical Cord Blood Stem Cell Transplantation: A Cohort Analysis. <i>Blood</i> , 2006, 108, 2929-2929.	0.6	1
222	Primary Treatment of Invasive Mucormycosis (IM) with Isavuconazole (VITAL Study) or Amphotericin Formulations (FungiScope [®]): Case Matched Analysis. <i>Blood</i> , 2014, 124, 1151-1151.	0.6	1
223	Next-Generation Sequencing for the Identification of Transplantation-Associated Pathogens. <i>Blood</i> , 2012, 120, LBA-4-LBA-4.	0.6	1
224	72. Remdesivir vs Standard Care in Patients with Moderate covid-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, S166-S167.	0.4	1
225	The relationship between antibiotic agent and mortality in patients with febrile neutropenia due to Staphylococcal bloodstream infection: a multicenter cohort study. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	1
226	Positively false. <i>Journal of Hospital Medicine</i> , 2009, 4, 194-199.	0.7	0
227	Thriving On Steroids: An Unexpected Case Of Disseminated Strongyloidiasis. , 2011, , .		0
228	Sequence-Based Discovery of Novel Bacteria, <i>Bradyrhizobium Enterica</i> , in Cord Colitis Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S281-S282.	2.0	0
229	Sociodemographics and epidemiology of serious infections requiring hospitalization among adults with systemic lupus erythematosus and lupus nephritis, 2000 to 2006. <i>Arthritis Research and Therapy</i> , 2014, 16, A37.	1.6	0
230	Adenovirus (ADV) Infection and Disease after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Epidemiology and Predictors of Mortality. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
231	Examining the In Vitro Volatile Metabolite Profile of Pathogenic <i>Scedosporium</i> and <i>Lomentospora</i> Species. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
232	Donor CMV Serostatus and Dose Adjustments in CMV Prophylaxis Increase CMV Infection Risk after Lung Transplantation. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
233	Safety of Live-attenuated Zoster Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide after Autologous Stem Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
234	Safety of MMR Vaccination in Multiple Myeloma Patients Receiving Maintenance Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0

#	ARTICLE	IF	CITATIONS
235	Safety of Foscarnet (FOS) Treatment for Human Herpesviruses (HHV) in a Contemporary Cohort of Immunocompromised Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
236	Cytomegalovirus Reactivation Does Not Reduce the Risk of Disease Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S329.	2.0	0
237	Introducing the Wiley Transplant Peer Review Network. <i>Transplant International</i> , 2016, 29, 839-841.	0.8	0
238	Norovirus Infection in Transplantation: Prolonged and Morbid Diarrhea. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
239	Introducing The Wiley Transplant Peer Review Network. <i>Artificial Organs</i> , 2016, 40, 635-637.	1.0	0
240	Utility of in-house fluconazole disk diffusion susceptibility testing in the treatment of candidemia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 223-226.	0.8	0
241	1140. GATA2 Mutations Are Frequently Identified Among Patients With Myeloid Malignancies Who Develop Invasive Aspergillosis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S342-S342.	0.4	0
242	1576. Risk of Clinical Tuberculosis (TB) Among Patients with Latent TB Infection (LTBI) Who Undergo Allogeneic Hematopoietic-Cell Transplantation (HCT). <i>Open Forum Infectious Diseases</i> , 2018, 5, S492-S492.	0.4	0
243	1557. Acyclovir-Resistant (ACV-R) Herpes Simplex Virus (HSV) Disease in Patients with Hematologic Malignancies (HM) and Hematopoietic-Cell Transplant (HCT) Recipients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S484-S484.	0.4	0
244	408. Invasive Fungal Petrositis and Carotiditis (IFPAC) Syndrome in Immunocompromised Hosts: An Unrecognized, Often Catastrophic Invasive Fungal Disease (IFD). <i>Open Forum Infectious Diseases</i> , 2018, 5, S156-S156.	0.4	0
245	Authors'™ Response. <i>Journal of Thoracic Oncology</i> , 2018, 13, e237.	0.5	0
246	Case 5-2018: A Man with Confusion after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2018, 378, 2544-2545.	13.9	0
247	Reply to Aronson et al. <i>Clinical Infectious Diseases</i> , 2020, 70, 1262.	2.9	0
248	A Post-Hoc Analysis of the Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Trial to Examine the Effects of DAS181 in Hematopoietic Cell Transplant (HCT) Recipients with Parainfluenza Virus (PIV) Lower Respiratory Tract Infection (LRTI) on Supplemental Oxygen (SO). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S75.	2.0	0
249	2453. Prolonged Local Epidemic of an XDR <i>P. aeruginosa</i> Subclade of High-Risk Clonal Complex 298. <i>Open Forum Infectious Diseases</i> , 2019, 6, S848-S848.	0.4	0
250	2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy. <i>Open Forum Infectious Diseases</i> , 2019, 6, S902-S902.	0.4	0
251	269. Epidemiology and Outcomes of Invasive Aspergillosis (IA) Among Pediatric Immunocompromised Patients: A 12-Year, Single-Center Experience. <i>Open Forum Infectious Diseases</i> , 2019, 6, S149-S149.	0.4	0
252	1024. Evaluation of Atovaquone Prescribing for <i>Pneumocystis jirovecii</i> Pneumonia (PJP) Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2019, 6, S360-S361.	0.4	0

#	ARTICLE	IF	CITATIONS
253	Missing the Target. <i>New England Journal of Medicine</i> , 2020, 382, 1353-1359.	13.9	0
254	Adenovirus Infections in Patients Undergoing Umbilical Cord Blood Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2009, 114, 1132-1132.	0.6	0
255	Cord Colitis: An Antibiotic-Responsive Colitis Syndrome Following Cord Blood Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 1270-1270.	0.6	0
256	HHV-6-Associated Post-Transplantation Acute Limbic Encephalitis Following Cord Blood Stem Cell Transplantation: A Cohort Analysis. <i>Blood</i> , 2011, 118, 649-649.	0.6	0
257	Pre-Emptive Rituximab for the Prevention of EBV-Related PTLD in Umbilical Cord Blood Transplantation Patients. <i>Blood</i> , 2011, 118, 3031-3031.	0.6	0
258	BK Virus Disease Following Allogeneic Stem Cell Transplantation: A Cohort Analysis. <i>Blood</i> , 2012, 120, 1927-1927.	0.6	0
259	BK Virus Reactivation After Double Umbilical Cord Blood Transplantation in Adults Correlates with Tregs and Delayed Reconstitution of CD4+ and CD8+ T Effector Cells. <i>Blood</i> , 2012, 120, 4174-4174.	0.6	0
260	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3425-3425.	0.6	0
261	Missing the Target. <i>New England Journal of Medicine</i> , 2020, 382, e23.	13.9	0
262	195. Economic and Clinical Burden of Respiratory Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Open Forum Infectious Diseases</i> , 2020, 7, S226-S226.	0.4	0
263	186. Evaluating Clinical Outcomes for Treatment of Staphylococcal Bloodstream Infection in Patients with Febrile Neutropenia. <i>Open Forum Infectious Diseases</i> , 2021, 8, S201-S201.	0.4	0
264	711. A Unique Breath Secondary Metabolite Volatile Signature for the Diagnosis of Histoplasmosis. <i>Open Forum Infectious Diseases</i> , 2021, 8, S454-S455.	0.4	0
265	992. Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI). <i>Open Forum Infectious Diseases</i> , 2021, 8, S586-S587.	0.4	0
266	1399. Clarithromycin-Rifampin-based Treatment for Non-tuberculous Mycobacterial Infections in Immunocompromised Patients Who Require Concomitant CYP-Metabolized Medications. <i>Open Forum Infectious Diseases</i> , 2021, 8, S784-S784.	0.4	0
267	Clarithromycin-Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab582.	0.4	0